hs6st2 Antibody

What is HS6ST2 and why is it significant in biomedical research?

HS6ST2 (Heparan Sulfate 6-O-Sulfotransferase 2) is an enzyme that catalyzes the transfer of sulfate groups to specific positions on heparan sulfate, a key component of the extracellular matrix and cell surfaces. This enzyme plays crucial roles in regulating cell growth, differentiation, adhesion, and migration through its sulfation activity . Recent pan-cancer analyses have revealed that HS6ST2 expression is dysregulated in multiple cancer types, demonstrating significant correlations with patient prognosis, tumor immune microenvironment, and drug sensitivity . The enzyme's involvement in tumor immunology processes makes it particularly interesting for cancer immunotherapy research. Additionally, HS6ST2 has been linked to intellectual disability, as evidenced by studies investigating HS6ST2 knockout mice .

What types of HS6ST2 antibodies are available for research applications?

Multiple types of HS6ST2 antibodies are currently available for research use, each with specific characteristics and applications:

Both antibodies are provided unconjugated and have been affinity-purified to ensure specificity for HS6ST2 . When selecting an antibody, researchers should consider their target species, application of interest, and the specific domains of HS6ST2 they wish to detect.

What are the recommended storage and handling conditions for HS6ST2 antibodies?

Proper storage and handling of HS6ST2 antibodies are essential for maintaining their activity and specificity. For the goat polyclonal antibody (R&D Systems AF2710), it is recommended to use a manual defrost freezer and avoid repeated freeze-thaw cycles. The antibody remains stable for 12 months from the date of receipt when stored at -20°C to -70°C . After reconstitution at 0.2 mg/mL in sterile PBS, the antibody can be stored for 1 month at 2-8°C or for 6 months at -20°C to -70°C under sterile conditions .

For the rabbit polyclonal antibody (STJ192487), storage at -20°C for up to 1 year from the date of receipt is recommended, also avoiding repeated freeze-thaw cycles . This antibody is supplied in liquid form in PBS containing 50% glycerol and 0.02% sodium azide . Always adhere to the manufacturer's specific storage recommendations to ensure antibody performance across experiments.

What are the optimal working dilutions for different experimental applications of HS6ST2 antibodies?

Determining the optimal working dilution for HS6ST2 antibodies is crucial for achieving specific detection while minimizing background. Based on the available research tools:

These recommended dilutions serve as starting points and may require optimization based on your specific experimental conditions and sample types . When establishing optimal dilutions, it is advisable to perform a titration experiment using positive controls with known HS6ST2 expression levels to determine the concentration that provides the strongest specific signal with minimal background.

What is the recommended protocol for HS6ST2 immunohistochemistry in tissue samples?

For immunohistochemical detection of HS6ST2 in tissue samples, researchers have successfully employed the following methodology, as described in recent pan-cancer studies:

• Tissue preparation: Fix tissue samples in formalin for morphological preservation .

• Antigen retrieval: Perform heat-induced epitope retrieval to expose the HS6ST2 antigen sites, which enhances antibody binding .

• Blocking: Block nonspecific binding sites with 10% goat serum to minimize false positives .

• Primary antibody incubation: Apply HS6ST2 primary antibody (recommended dilution 1:200 for Abcam antibodies) and incubate overnight at 4°C .

• Washing: Wash samples three times with PBS for 5 minutes each to remove unbound antibodies .

• Secondary antibody incubation: Apply HRP-labeled secondary antibodies (recommended dilution 1:100) and incubate for 30 minutes at room temperature .

• Final washing: Perform 4-8 washes with PBS for 5 minutes each to eliminate unbound secondary antibodies and reduce background .

• Visualization and counterstaining: Develop with an appropriate substrate and counterstain as needed for tissue architecture visualization.

This protocol has been validated for detecting HS6ST2 in lung adenocarcinoma (LUAD) tissues and can be adapted for other tissue types with appropriate controls .

How should RT-qPCR experiments be designed to analyze HS6ST2 expression in clinical samples?

When designing RT-qPCR experiments to analyze HS6ST2 expression in clinical samples, researchers should follow these methodological considerations:

• Sample collection and processing: Collect matched tumor and adjacent normal tissue samples with proper ethical approval. Fresh tissue samples should be immediately processed or stored appropriately to preserve RNA integrity .

• RNA extraction: Isolate RNA using the Trizol extraction method, which has been successfully applied in HS6ST2 expression studies .

• cDNA synthesis: Reverse transcribe the extracted RNA into cDNA using a reliable reverse transcription kit .

• Primer design: Design specific primers for HS6ST2 and appropriate housekeeping genes for normalization. Ensure primers span exon-exon junctions to avoid genomic DNA amplification.

• PCR conditions: Optimize PCR reaction mixture and cycling conditions for your specific primers and template concentration .

• Data analysis: Use the comparative Ct method (2^-ΔΔCt) for relative quantification of HS6ST2 expression, normalizing to housekeeping genes and appropriate reference samples.

• Validation: Confirm RT-qPCR findings with protein-level detection methods like Western blot or immunohistochemistry to establish concordance between mRNA and protein expression .

This approach has been validated in studies examining HS6ST2 expression in lung adenocarcinoma and other cancer types, providing reliable quantification of expression differences between tumor and normal tissues .

How can HS6ST2 expression be correlated with immune cell infiltration in tumor microenvironments?

Analyzing correlations between HS6ST2 expression and immune cell infiltration requires integrated bioinformatic and experimental approaches:

• Bioinformatic analysis: Utilize the TIMER2.0 algorithm (http://timer.cistrome.org/) to assess correlations between HS6ST2 expression and immune cell infiltration across different cancer types in TCGA databases . This tool provides quantitative estimates of immune cell abundance based on gene expression profiles.

• Immune cell subtypes: Focus analysis on key immune cell populations including CD8+ T cells, CD4+ T cells, B cells, macrophages, neutrophils, and dendritic cells to comprehensively characterize the immune microenvironment .

• Correlation analysis: Calculate Spearman's correlation coefficients between HS6ST2 expression levels and immune cell infiltration scores to identify significant associations .

• Experimental validation: Confirm bioinformatic findings using multiplex immunofluorescence or flow cytometry on tissue samples to directly quantify immune cell populations in relation to HS6ST2 expression.

Recent pan-cancer analyses have revealed positive correlations between HS6ST2 expression and infiltration of CD8+ T and CD4+ T cells specifically in cervical squamous cell carcinoma (CESC), kidney chromophobe (KICH), lung adenocarcinoma (LUAD), and stomach adenocarcinoma (STAD) . These findings suggest that HS6ST2 may play a role in modulating the tumor immune microenvironment, with potential implications for immunotherapy response.

What is the prognostic significance of HS6ST2 expression across different cancer types?

The prognostic significance of HS6ST2 varies across cancer types, reflecting its context-dependent roles in cancer biology:

To investigate HS6ST2's prognostic value:

• Expression analysis: Use tools like GEPIA2 and UALCAN to evaluate HS6ST2 expression differences between tumor and normal tissues, as well as across tumor stages .

• Survival analysis: Perform Kaplan-Meier survival analysis stratifying patients by HS6ST2 expression levels (high vs. low), calculating hazard ratios and statistical significance.

• Multivariate analysis: Adjust for clinical covariates (age, stage, grade) using Cox proportional hazards models to determine if HS6ST2 is an independent prognostic factor.

• Subgroup analysis: Examine prognostic significance within specific molecular subtypes, stages, or treatment groups to identify contexts where HS6ST2 has stronger prognostic value.

Recent pan-cancer studies have demonstrated that elevated HS6ST2 expression is significantly associated with poorer outcomes in certain cancer types, highlighting its potential utility as a prognostic biomarker in clinical practice .

How does HS6ST2 expression correlate with drug sensitivity in cancer cell lines?

HS6ST2 expression shows significant correlations with drug sensitivity profiles across multiple cancer types, offering potential guidance for precision medicine approaches:

• Bioinformatic analysis: Utilize the GSCAlite database (http://bioinfo.life.hust.edu.cn/web/GSCALite/) to establish correlations between HS6ST2 mRNA expression and drug response data from cancer cell line databases .

• Drug class analysis: Examine whether HS6ST2 expression correlations are specific to certain drug classes (targeted therapies, chemotherapeutics, immunotherapies) to identify potential mechanism-based relationships.

• Positive vs. negative correlations: Distinguish between drugs where high HS6ST2 predicts sensitivity versus resistance to develop hypotheses about underlying mechanisms.

• Experimental validation: Confirm bioinformatic findings through in vitro drug sensitivity assays in cell lines with manipulated HS6ST2 expression (knockdown, overexpression) to establish causality.

Recent analyses have indicated that HS6ST2 expression levels are associated with varied responses to specific therapeutic agents, suggesting its potential utility in predicting treatment outcomes and guiding personalized therapy selection . The mechanistic basis for these correlations likely involves HS6ST2's role in modifying the extracellular matrix and cellular signaling pathways that influence drug uptake, retention, or downstream effects.

What are common pitfalls when using HS6ST2 antibodies and how can they be addressed?

When working with HS6ST2 antibodies, researchers commonly encounter several challenges that can be systematically addressed:

• Non-specific binding:

  • Cause: Insufficient blocking or overly concentrated primary antibody

  • Solution: Optimize blocking conditions (use 10% goat serum as demonstrated in successful protocols) and titrate antibody concentrations carefully

• Weak or inconsistent signals in Western blots:

  • Cause: Insufficient antigen, protein degradation, or inefficient transfer

  • Solution: Ensure proper sample preparation and loading, use positive controls (such as tissues known to express HS6ST2), and optimize transfer conditions for high molecular weight proteins

• High background in immunohistochemistry:

  • Cause: Inadequate washing or endogenous peroxidase activity

  • Solution: Implement more stringent washing steps (4-8 PBS washes for 5 minutes each) and properly quench endogenous peroxidase activity

• Cross-reactivity with related sulfotransferases:

  • Cause: Antibody recognizing conserved domains in related proteins

  • Solution: Validate antibody specificity using knockout or knockdown controls; compare results with multiple antibodies targeting different epitopes

• Variability between experiments:

  • Cause: Inconsistent antibody quality between lots or degradation during storage

  • Solution: Aliquot antibodies upon receipt, avoid repeated freeze-thaw cycles, and include standardized positive controls in each experiment

These solutions are based on successful methodologies reported in recent HS6ST2 research publications and manufacturer recommendations .

How should researchers interpret discrepancies between HS6ST2 mRNA expression and protein detection?

Discrepancies between HS6ST2 mRNA and protein levels are common and can provide valuable biological insights when properly interpreted:

• Post-transcriptional regulation:

  • HS6ST2 may be subject to miRNA-mediated repression or RNA-binding protein regulation affecting translation efficiency

  • Analysis of RNA methylation-related genes has shown correlations with HS6ST2 expression in multiple cancer types, suggesting epigenetic regulation at the mRNA level

• Protein stability and turnover:

  • Differences in protein half-life versus mRNA stability can lead to temporal disconnects between transcript and protein abundance

  • Examine ubiquitination pathways or proteasomal degradation that might specifically target HS6ST2

• Technical considerations:

  • Different sensitivities between RT-qPCR and Western blot/IHC methods

  • Ensure antibodies recognize all relevant isoforms or post-translationally modified versions of HS6ST2

• Spatial heterogeneity:

  • In tissue samples, consider whether sampling regions for RNA and protein analyses are comparable, especially given potential heterogeneity in HS6ST2 expression within tumors

• Validation approach:

  • When discrepancies arise, employ multiple detection methods (Western blot, IHC, ELISA) using different antibodies targeting distinct epitopes

  • Consider single-cell approaches to resolve population heterogeneity that might explain bulk measurement discrepancies

Recent pan-cancer studies have utilized both RT-qPCR and immunohistochemistry for validation, finding general concordance between mRNA and protein levels in lung adenocarcinoma samples, though with some variation in magnitude .

How can researchers distinguish between HS6ST2 and other sulfotransferase family members in experimental data?

Distinguishing HS6ST2 from related sulfotransferases requires careful experimental design and validation:

• Antibody specificity:

  • Select antibodies targeting unique regions of HS6ST2 (e.g., the rabbit polyclonal antibody targeting amino acids 140-220)

  • Validate antibody specificity using overexpression and knockdown controls for HS6ST2 and related family members (HS3ST1, HS2ST1)

• Primer design for RT-qPCR:

  • Design primers targeting unique regions with minimal sequence homology to other sulfotransferases

  • Validate primer specificity using in silico analysis (BLAST) and experimental controls

  • Include melt curve analysis to confirm amplification of a single specific product

• Comparative analysis:

  • Simultaneously analyze multiple sulfotransferase family members (HS6ST2, HS3ST1, HS2ST1) as performed in recent studies

  • Look for divergent expression patterns or functional effects that distinguish HS6ST2

• Functional validation:

  • Use specific enzymatic activity assays that distinguish 6-O-sulfation from other sulfation patterns

  • Employ CRISPR/Cas9 gene editing to create specific knockouts for functional validation

• Cellular localization:

  • HS6ST2 is a membrane-associated single-pass type II membrane protein

  • Use subcellular fractionation or co-localization studies to confirm expected localization patterns distinct from other family members

These approaches have been successfully employed in research differentiating between various heparan sulfate sulfotransferases in cancer studies and can help ensure that observed effects are specifically attributable to HS6ST2 rather than related family members .

What are emerging areas of HS6ST2 research beyond cancer applications?

While cancer research has dominated recent HS6ST2 studies, several emerging areas represent promising directions for future investigation:

• Neurodevelopmental disorders:

  • Recent research has begun exploring HS6ST2 knockout in mice in relation to intellectual disability

  • Future studies could investigate how HS6ST2-mediated heparan sulfate modifications influence neural development, synaptic plasticity, and cognitive function

• Inflammatory and immune disorders:

  • Given HS6ST2's correlation with immune cell infiltration in tumors , its role in normal immune system development and inflammatory conditions warrants investigation

  • Potential applications in autoimmune disease research where extracellular matrix modifications may influence immune cell trafficking and activation

• Developmental biology:

  • HS6ST2's role in cell differentiation and migration suggests important functions during embryogenesis and organogenesis

  • Transgenic models with tissue-specific or inducible HS6ST2 manipulation could reveal stage-specific developmental requirements

• Therapeutic target development:

  • Small molecule inhibitors targeting HS6ST2 enzymatic activity could be developed as research tools and potential therapeutic agents

  • Antibody-drug conjugates targeting HS6ST2 could provide selective delivery of cytotoxic agents to tumor cells with high expression

• Biomarker development in non-cancer conditions:

  • Evaluating HS6ST2 expression or activity as potential biomarkers for neurological disorders, inflammatory conditions, or developmental abnormalities

These emerging areas represent logical extensions of current HS6ST2 knowledge into new domains of biomedical research, potentially revealing novel functions and therapeutic applications beyond oncology.

How can single-cell analysis techniques advance our understanding of HS6ST2 function?

Single-cell analysis technologies offer powerful approaches to elucidate HS6ST2 biology with unprecedented resolution:

• Single-cell RNA sequencing (scRNA-seq):

  • Recent pan-cancer analyses have already begun applying single-cell functional states analysis to HS6ST2

  • Future applications can identify cell-type specific expression patterns and co-expression networks

  • CancerSEA has been used to analyze associations between HS6ST2 and diverse cellular processes at the single-cell level

• Spatial transcriptomics:

  • Combining HS6ST2 expression data with spatial information can reveal microenvironmental contexts influencing its expression

  • Particularly valuable for understanding HS6ST2's role at tumor-stroma interfaces and in relation to immune cell infiltration

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) or multiplexed immunofluorescence can quantify HS6ST2 protein levels alongside other markers

  • Reveals heterogeneity in expression within phenotypically similar cell populations

• Functional genomics at single-cell resolution:

  • CRISPR screens with single-cell readouts can identify genetic interactions with HS6ST2

  • Potential to discover context-dependent requirements for HS6ST2 function

• Integrated multi-omics approaches:

  • Combining scRNA-seq with epigenomic profiling to understand regulatory mechanisms controlling HS6ST2 expression

  • Correlating HS6ST2 expression with metabolomic or proteomic data at single-cell resolution

These advanced techniques can resolve heterogeneity masked in bulk analyses and reveal how HS6ST2 function varies across cell states, tissue contexts, and disease progression. Single-cell approaches have already demonstrated associations between HS6ST2 and diverse cellular processes, providing a foundation for more detailed mechanistic studies .

What methodological advances are needed to better understand the mechanistic role of HS6ST2 in disease pathogenesis?

Several methodological advances would significantly enhance our understanding of HS6ST2's mechanistic contributions to disease:

• Improved structural biology approaches:

  • Crystal structures or cryo-EM studies of HS6ST2 alone and in complex with substrates would provide insights into catalytic mechanisms

  • Structure-guided design of specific inhibitors or activity probes

• Advanced glycomics techniques:

  • More sensitive methods to profile heparan sulfate sulfation patterns in small tissue samples

  • Site-specific analysis of sulfation changes mediated by HS6ST2 alteration

  • Mass spectrometry approaches to quantify changes in the "sulfation code" of heparan sulfate

• Systems for conditional manipulation of HS6ST2:

  • Inducible and cell-type specific knockout or overexpression models

  • CRISPR-based approaches for precise editing of catalytic domains versus protein interaction domains

• Protein interaction mapping:

  • Proximity labeling approaches (BioID, APEX) to identify HS6ST2 interaction partners in living cells

  • Analysis of how these interactions change during disease progression

• Functional assays for HS6ST2-modified heparan sulfate:

  • Development of biosensors or reporter systems to track HS6ST2 activity in real-time

  • Methods to distinguish biological effects of 6-O-sulfation from other modifications

• Translational models:

  • Patient-derived organoids or xenografts with manipulated HS6ST2 expression

  • Humanized mouse models for studying HS6ST2 in immune contexts

These methodological advances would bridge current gaps between descriptive correlations and mechanistic understanding, potentially accelerating the development of HS6ST2-targeted diagnostics and therapeutics across multiple disease areas.